WO1993001819A1 - Utilisation de composes a base de silicium dans la prevention de lesions traumatiques - Google Patents

Utilisation de composes a base de silicium dans la prevention de lesions traumatiques Download PDF

Info

Publication number
WO1993001819A1
WO1993001819A1 PCT/US1992/005179 US9205179W WO9301819A1 WO 1993001819 A1 WO1993001819 A1 WO 1993001819A1 US 9205179 W US9205179 W US 9205179W WO 9301819 A1 WO9301819 A1 WO 9301819A1
Authority
WO
WIPO (PCT)
Prior art keywords
animal
zeolite
animals
silicon compound
human
Prior art date
Application number
PCT/US1992/005179
Other languages
English (en)
Inventor
Karl E. Wiegand
Original Assignee
Ethyl Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethyl Corporation filed Critical Ethyl Corporation
Priority to EP92914022A priority Critical patent/EP0594659A1/fr
Priority to JP5502466A priority patent/JPH06509103A/ja
Publication of WO1993001819A1 publication Critical patent/WO1993001819A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A23K20/30—Oligoelements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/015—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to the prevention and reduction of susceptibility to traumatic injury by the administration of silicon compounds.
  • silicate compounds have been reported to elevate blood, serum, plasma or urine levels of silicon when administered orally or by injection. These include sodium silicate, magnesium silicate, amorphous sodium aluminosilicate, and sodium zeolite A. Behnke and Osborn showed that sodium zeolite A was particularly effective in this regard. See Behnke, et al., Food. Cosm. Toxicol.. 17, 123-127, (1979).
  • No.4,393,082 issued July 12, 1983 discloses the use of zeolites having exchangeable cations as a feed component in the feeding of urea or biuret non-protein nitrogen (NPN) compounds to ruminants, such as cattle, sheep and goats.
  • NPN non-protein nitrogen
  • Natural and synthetic as well as crystalline and non-crystalline zeolites are disclosed.
  • Zeolites tested using in vitro techniques included natural zeolites, chabazite and clinoptilolite and synthetic zeolites X, Y, F, J, M, Z and A. Zeolite F was by far the most outstanding. Zeolite A was substantially ineffective.
  • U.S. Pat. No. 4,847,085 discloses a method of improving the quality of the bones and/or increasing the bone strength of animals, including humans, cattle, sheep, goats, swine and poultry, without deleterious effects on the animals or products of the animals by adding a small, effective amount of zeolite to the feed of the animals or directly to the animals in the form of a capsule, tablet or the like.
  • the spaces between the tetrahedra are occupied by water molecules prior to dehydration.
  • zeolites There are a number of different types of zeolites. Some zeolites are found in nature and can also be made synthetically. Other zeolites are made only synthetically. Zeolite A is not found in nature and is made only synthetically.
  • U.S. Pat. No. 4,847,085 discloses the nutritional uses of zeolites to strengthen bone. That patent references the variety and types of zeolites useful in the disclosed method and processes used to prepare such zeolites. It is an important object of this invention to provide a method for treating, preventing or delaying the effects of traumatic injury to the tissues of animals, including humans, by treatment of the animals with a relatively small amount of silicic acid produced by administering to the animal to be subjected to trauma- producing conditions metal silicates or aluminosilicates, especially zeolites. It is an object of the invention to provide an animal treatment or food containing zeolite, which inhibits the effects of traumatic injury in animals, especially humans.
  • Another object of the invention is to provide a process for the treatment and/or prevention of the effects of traumatic injury to both hard and soft tissue in animals wherein an effective amount of zeolite is added to the diet of the animal.
  • Still another object of the invention is to effectively treat, prevent or delay traumatic injury to the tissue of animals without causing any deleterious effects in the animals.
  • Yet a further object of the present invention is to treat, prevent or delay the traumatic injury to the tissue of equine ammals.
  • the present invention relates to a method of treating, preventing or delaying the traumatic injury to the tissue of animals, especially humans, by treating the animal with an effective amount of silicic acid produced by administering to the animal a silicon-containing compound.
  • the silicic acid preferably is formed after administering to the animal to be subjected to trauma-causing conditions a physiologically acceptable silicon-containing compound that results in the formation (within the animal) of an effective amount of silicic acid.
  • the silicon-containing compounds employed in this invention are those that are non-toxic and physiologically acceptable and, when administered to the animal, provide the animal with a source of silicic acid.
  • the silicon-containing compounds can be entirely inorganic or organic silicon compounds.
  • silicate esters are preferred and orthosilicates are particularly preferred, i.e., compounds of the formula Si(OR) 4 where R is an organic radical, such as to C 6 linear or branched alkyl (methyl, ethyl, or n-propyl). More than one type of R group may be combined.
  • metal alumino- silicates are preferred. These include metals of Group IA, such as sodium or potassium, and metals of Group HA, such as calcium and magnesium. Examples of such compounds are potassium aluminosilicate, sodium aluminosilicate, calcium aluminosilicate and magnesium aluminosilicate.
  • the zeolites, particularly zeolite A are included within such class of inorganic silicates.
  • Administration may be by way of pellets, powder, tablets or capsules.
  • Traumatic injury among race horses is well known to be a common occurrence.
  • the following treatments were carried out.
  • the silicic acid was generated within the animal by administering increasing levels of sodium zeolite A to a group of equines and subjecting them to a standardized regimen of training. It should be understood that the following examples are for the purpose of illustration only. They are not intended to limit this invention in any way.
  • EXAMPLE 1 Starting at approximately six months of age, a group of Quarter Horses were administered a diet of concentrate and hay balanced to NRC guidelines [National Research Council (U.S.) (1989) Nutritional Requirements of Horses. National Academy Press, Washington, D.C.] supplemented with varying levels of sodium zeolite A(ZA). Animals were fed twice daily in individual stalls and otherwise allowed to exercise in a dry paddock. ZA constituted approximately 0, 0.66, 1.33, or 2.0 percent of their feed intake. Feed was composed of 75% concentrate and 25% coastal bermuda grass hay.
  • the concentrate portion of the diet was composed of 87% pelleted concentrate (from corn, wheat mids, soybean meal, alfalfa meal, lignin binder, vitamin supplement, ground limestone and trace mineralized salt) and of 13% supplement of sodium zeolite A pelleted with dried alfalfa. Loading of 0, 6.6, 13.3 and 20% sodium zeolite A in the alfalfa pellets was used to allow constant volumes of supplement while varying the dose level of ZA. Feeding rates were increased as the animals grew so as to maintain approximately constant dosing on a body weight basis.
  • mice were fed approximately 0.2% of their body weight as (zeolite A-containing) supplement each day as part of the concen-trate portion of their diet (including the 0 dose supplement).
  • concentration of zeolite A in the supplement is from 6% to 20% by weight (this represents a dose of zeolite A of 0.12% to 0.4% as a fraction of the body weight).
  • the treatments were labelled by drawing lots as A, B, D, C, respectively.
  • Horses were randomly assigned to treatment, blocked by sex, weight and body condition score. Males were gelded at 1 year of age. After six months of treatment, animals, now approximately one year of age, were transferred to large forage- containing paddocks and fed again to NRC requirements with a combination of ad libitum hay and concentrate. Twice daily the horses were each provided 1.82 kg per head of concentrate feed (approximately 1% of body weight over a 180-day period). Animals were again provided with 0.2% of their body weight as the zeolite A-containing supplement (including the 0 dose supplement) in this concentrate. The ratio of supplement to the rest of the concentrate was increased to 20:80 to adjust for the changing nutritional requirements in horses of this age.
  • mice were entered into a breaking/training/ racing program and conditioned to race from a starting gate. After 17 weeks of breaking and training (9 weeks of breaking and 8 weeks of combined long, slow distance and sprint conditioning and gate training), animals entered a racing program. Animals were raced on alternate weeks. During the week of the race, the following schedule was maintained: day 1 - warm up and gallop 1 mile; day 2 - walk 1 hour on the walker; day 3 - warm up, gallop 1/2 mile and sprint 150 yards; days 4 and 5 - walk; day 6 - race; day 7 - stall rest. Races were run at increasing distances as follows: races 1-3, 300 yards; races 4-6, 350 yards; races 7-9, 400 yards. Alternate weeks with no race the weekly schedule was: days 1 and 3 - warm up and gallop 1.5 miles; days 2, 4, 6 and 7 - walk; day 5 - warm up, gallop 1/2 mile and sprint 200 yards.
  • the concentrate portion of the diet was composed of a 20:80 ratio of pelleted zeolite A-containing supplement to pelleted concentrate.
  • the treatment regimen was maintained throughout the study. Trainers, jockeys, veterinarians and other personnel involved in handling, diagnosis and treatment were blinded as to the composition of the treatments.
  • mice were assessed. They were defined to have been injured if as a result of training or racing at some point they were unable to perform at speed as a result of trauma induced by the galloping/sprinting activity. At this point, the beginning horses had completed eight races and the last entries had completed three races. Both soft and hard tissue injuries were counted. Percent injured within each group was assessed as was the distance and the number of strides to injury. One animal sustained an injury in an accident on the walker. It was not included in the analysis. Another animal was injured before entering the galloping/sprinting phase of the study, but recovered sufficiently to continue a normal training/racing activity. This animal was included in the analysis. Use of distance or strides run before first injury allowed comparison regardless of progress within the race schedule.
  • Plasma silicon levels after 84 days of treatment were: P as a Si m
  • the treatment leads to a dose related increase in the mean plasma level of silicon in treated horses.
  • the increase of systemic silicon level is associated with the reduction of susceptibility to traumatic ° injury noted in Example 1.
  • the usefulness of this invention is general. This is due to the common elements of traumatic injury, regardless of cause. Accordingly, the usefulness of this invention is not limited to athletic injury. Other applications include improved resistance to tissue damage in animals such as poultry, cattle, horses, pigs and humans during transportation, improved resistance to traumatic injury due to falls and so on.

Abstract

Procédé pour traiter, prévenir ou retarder une lésion traumatique occasionnée dans le tissu d'un animal, particulièrement chez l'homme, les équidés ou animaux analogues, comprenant le traitement dudit animal avec une quantité efficace d'acide silicique produite par ledit animal à partir d'un composé de silicium administré audit animal.
PCT/US1992/005179 1991-07-15 1992-06-16 Utilisation de composes a base de silicium dans la prevention de lesions traumatiques WO1993001819A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP92914022A EP0594659A1 (fr) 1991-07-15 1992-06-16 Utilisation de composes a base de silicium dans la prevention de lesions traumatiques
JP5502466A JPH06509103A (ja) 1991-07-15 1992-06-16 外傷性損傷の予防および重症度の減少

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73008591A 1991-07-15 1991-07-15
US730,085 1991-07-15

Publications (1)

Publication Number Publication Date
WO1993001819A1 true WO1993001819A1 (fr) 1993-02-04

Family

ID=24933845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/005179 WO1993001819A1 (fr) 1991-07-15 1992-06-16 Utilisation de composes a base de silicium dans la prevention de lesions traumatiques

Country Status (4)

Country Link
EP (1) EP0594659A1 (fr)
JP (1) JPH06509103A (fr)
CA (1) CA2111972A1 (fr)
WO (1) WO1993001819A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795718B2 (en) 2008-05-22 2014-08-05 Honeywell International, Inc. Functional nano-layered hemostatic material/device
US8883194B2 (en) 2007-11-09 2014-11-11 Honeywell International, Inc. Adsorbent-containing hemostatic devices
WO2023012147A1 (fr) 2021-08-03 2023-02-09 F. Hoffmann-La Roche Ag Anticorps bispécifiques et procédés d'utilisation

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298673A1 (en) * 2002-11-18 2004-06-15 Grenpharma Llc Compositions for treating and/or preventing diseases characterized by the presence of metal ions
CN1245220C (zh) * 2003-04-09 2006-03-15 江苏阳生生物工程有限公司 促进皮肤创面快速修复的新型敷料材料
WO2012079121A1 (fr) * 2010-12-16 2012-06-21 Tuffrock Technology Pty Limited Composition améliorée à base de minéraux et procédés d'utilisation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847085A (en) * 1983-03-14 1989-07-11 Ethyl Corporation Bone disorder treatment
WO1989006965A1 (fr) * 1988-02-08 1989-08-10 Ethyl Corporation Composition de zeolite
US4870191A (en) * 1988-07-22 1989-09-26 Ethyl Corporation Silicon containing reaction product
WO1990000884A1 (fr) * 1988-07-22 1990-02-08 Ethyl Corporation Composes de silicium pour le traitement des os
US5082662A (en) * 1983-03-14 1992-01-21 Ethyl Corporation Bone disorder treatment
EP0497287A1 (fr) * 1991-01-28 1992-08-05 Finfonta Import Ky Additif alimentaire pour le renforcement des os et des articulations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847085A (en) * 1983-03-14 1989-07-11 Ethyl Corporation Bone disorder treatment
US5082662A (en) * 1983-03-14 1992-01-21 Ethyl Corporation Bone disorder treatment
WO1989006965A1 (fr) * 1988-02-08 1989-08-10 Ethyl Corporation Composition de zeolite
US4870191A (en) * 1988-07-22 1989-09-26 Ethyl Corporation Silicon containing reaction product
WO1990000884A1 (fr) * 1988-07-22 1990-02-08 Ethyl Corporation Composes de silicium pour le traitement des os
EP0497287A1 (fr) * 1991-01-28 1992-08-05 Finfonta Import Ky Additif alimentaire pour le renforcement des os et des articulations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883194B2 (en) 2007-11-09 2014-11-11 Honeywell International, Inc. Adsorbent-containing hemostatic devices
US8795718B2 (en) 2008-05-22 2014-08-05 Honeywell International, Inc. Functional nano-layered hemostatic material/device
WO2023012147A1 (fr) 2021-08-03 2023-02-09 F. Hoffmann-La Roche Ag Anticorps bispécifiques et procédés d'utilisation

Also Published As

Publication number Publication date
CA2111972A1 (fr) 1993-02-04
EP0594659A1 (fr) 1994-05-04
JPH06509103A (ja) 1994-10-13

Similar Documents

Publication Publication Date Title
US6524609B1 (en) Treating arthritis in animals with dietary supplements
CA2671747C (fr) Compositions pour alimentation animale
Nielsen et al. Training distance to failure in young racing quarter horses fed sodium zeolite A
WO1993001819A1 (fr) Utilisation de composes a base de silicium dans la prevention de lesions traumatiques
McDowell et al. Selenium availability and methods of selenium supplementation for grazing ruminants
CA2995626C (fr) Procedes et formulations permettant de reduire les emissions bovines
US20120328715A1 (en) Prevention and treatment of osteochondrosis in animals and humans
RU2259832C2 (ru) Препарат для усиления обменных процессов и иммунитета у сельскохозяйственных животных и птицы
Rezende et al. Effect of two different nutritional programs on orthopedic alterations in Mangalarga Marchador foals
JP2008541767A5 (fr)
Hintz Equine nutrition update
CA2314042C (fr) Nourriture pour chevaux
RU2182798C2 (ru) Способ нормализации обменных процессов у молодняка крупного рогатого скота
NL2007581C2 (en) Method for preventing osteochondrosis.
RU2435436C2 (ru) Кормовая композиция для профилактики или лечения ожирения у животного, способ профилактики или лечения ожирения у животного, композиция для саморегуляции потребления кормового продукта животным, способ саморегуляции потребления кормового продукта животным, набор, применение капсаициноида для получения кормовой композиции
Olson Effect of Sunlight on the Growth, Production and Reproductiion of Dairy Cattle
Hill et al. Effects of trace mineral supplements on performance of feedlot steers
EP2035019A1 (fr) Prévention et traitement de l'ostéochondrose chez l'homme et les animaux
JPS63502835A (ja) 家畜の商業的性能を改善する免疫変調剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2111972

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992914022

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992914022

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992914022

Country of ref document: EP